Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list ...
US FDA says Lilly's weight-loss drug no longer in shortage
Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...
BioSpace1h
Lilly’s Tirzepatide No Longer on FDA Drug Shortage List
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...
Eat first, test later: How the FDA’s food regulatory system is broken
A regulatory loophole allows manufacturers to add untested ingredients to food that are later found to be dangerous. Here’s ...
Guacamole Recall Update as FDA Sets Highest Risk Level
The guacamole, peppers, and vegetables voluntarily recalled by the maker have been classed as the highest risk level by the ...
FDA approves BioIntelliSense’s BioButton wearable for patient monitoring
BioIntelliSense has received approval from the US Food and Drug Administration (FDA) for its BioButton Multi-Patient wearable ...
Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
Elucid scoops FDA approval for AI cardiovascular risk diagnostic
Elucid’s AI software helps physicians visualise arterial plaque build-up to assess patients’ risk of cardiovascular disease ...
Food Safety News9h
FDA streamlines consumer complaint process
As part of the FDA’s new Human Foods Program reorganization, which went into effect Oct. 1, the agency has announced a ...
Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment
Aldeyra Therapeutics has once again filed for Food and Drug Administration of its proposed reproxalap drug candidate for the treatment of signs and symptoms of dry-eye disease.
HIms and Hers shares drop after FDA says Lilly's weight-loss drug not in shortage
Shares in telehealth group Hims & Hers Health (NYSE:HIMS) dropped in premarket US trading on Thursday after federal drug ...
FDA approves Dupixent for chronic obstructive pulmonary disease
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...